# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Finding useful health information on the Internet can be difficult, but we’re here to help. This page gathers quality information from trusted sources. You can learn more about the disease, visit handpicked websites, and find resources to help you in your daily life. Need more information? Click the menu on the left to find more!

 

Idiopathic pulmonary fibrosis

Familial pulmonary fibrosis
Get Update

Clinical Trials

This information is provided by ClinicalTrials.gov

Search Clinical Trials
Displaying 91-100 of 364 results.
Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed
Last Changed: Jun 13, 2018
First Received: Nov 05, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Nintedanib, Pirfenidone
Locations: David Geffen School of Medicine at UCLA;Division of Pulmonary & Critical Care/ Department of Medic, Los Angeles, California, United States
Stanford University School of Medicine ; Pulmonary/Critical Care Medicine, Stanford, California, United States
Sarasota Memorial Hospital, Sarasota, Florida, United States
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
University of Michigan Health System, Ann Arbor, Michigan, United States
... and 34 other locations.
A Study to Assess the Tolerability of a Single Dose of Gefapixant (AF-219/MK-7264) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Status: Completed
Last Changed: Jun 25, 2019
First Received: Jun 23, 2015
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Gefapixant
Locations: American Health Research, Charlotte, North Carolina, United States
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis
Status: No longer available
Last Changed: Feb 08, 2019
First Received: Sep 03, 2014
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): nintedanib
Locations: Centro Medico Santa Maria, Barra Mansa, Brazil
CLARE - Clinica de Pneumologia, Goiania, Brazil
Irmandade da Santa Casa de Misericórdia de Porto Alegre, Porto Alegre, Brazil
H.C.da Fac. de Medicina de Ribeirao Preto, Ribeirao Preto, Brazil
Universidade do Estado do Rio de Janeiro, Rio De Janerio, Brazil
... and 4 other locations.
Effect of Nintedanib on Biomarkers of Extracellular Matrix Turnover in Patients With Idiopathic Pulmonary Fibrosis and Limited Forced Vital Capacity Impairment
Status: Completed
Last Changed: Aug 06, 2019
First Received: Jun 02, 2016
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): nintedanib, placebo
Locations: Jasper Summit Research, LLC, Jasper, Alabama, United States
Western Connecticut Medical Group, Danbury, Connecticut, United States
St. Francis Medical Institute, Clearwater, Florida, United States
University of Florida College of Medicine, Jacksonville, Florida, United States
Minnesota Lung Center, Minneapolis, Minnesota, United States
... and 82 other locations.
Expanded Access Program of Nintedanib in Patients With Idiopathic Pulmonary Fibrosis (EAP)
Status: Approved for marketing
Last Changed: May 08, 2017
First Received: Jun 24, 2014
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): nintedanib
Locations: 1199.177.1003 Boehringer Ingelheim Investigational Site, Winter Park, Florida, United States
1199.177.1012 Boehringer Ingelheim Investigational Site, Skokie, Illinois, United States
1199.177.1014 Boehringer Ingelheim Investigational Site, Muncie, Indiana, United States
1199.177.1002 Boehringer Ingelheim Investigational Site, Minneapolis, Minnesota, United States
1199.177.1011 Boehringer Ingelheim Investigational Site, Charleston, South Carolina, United States
... and 3 other locations.
Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone
Status: Approved for marketing
Last Changed: Jul 13, 2015
First Received: May 19, 2014
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Pirfenidone
Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
Status: Completed
Last Changed: May 13, 2014
First Received: May 13, 2014
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Pirfenidone, placebo
Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF)
Status: Terminated
Last Changed: Apr 04, 2017
First Received: Jan 03, 2013
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Simtuzumab
Locations: Arizona Pulmonary Specialists, Ltd., Scottsdale, Arizona, United States
University of California, Los Angeles, California, United States
Stanford University Medical Center, Stanford, California, United States
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
Medical University of South Carolina, Charleston, South Carolina, United States
... and 2 other locations.
Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis
Status: Unknown status
Last Changed: May 13, 2014
First Received: May 09, 2014
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Autologous Stromal Vascular Fraction (SVF), Autologous Adipose Derived MSCs (ADMSCs), Control
Locations: Kasiak Research Pvt Ltd, Thane, Maharashtra, India
Efficacy and Safety of Nintedanib Co-administered With Sildenafil in Idiopathic Pulmonary Fibrosis Patients With Advanced Lung Function Impairment
Status: Completed
Last Changed: Jan 11, 2019
First Received: Jun 16, 2016
Disease(s): Idiopathic Pulmonary Fibrosis
Intervention(s): Nintedanib, Placebo, Sildenafil
Locations: University of Alabama at Birmingham, Birmingham, Alabama, United States
Pulmonary Assoc of Stamford, Stamford, Connecticut, United States
University of Florida College of Medicine, Jacksonville, Florida, United States
University of Chicago, Chicago, Illinois, United States
University of Kansas Medical Center, Kansas City, Kansas, United States
... and 81 other locations.